# A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

> **NCT00378092** · PHASE4 · COMPLETED · sponsor: **Janssen Cilag N.V./S.A.** · enrollment: 33 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Oral risperidone
- **DRUG:** Risperidone Long-Acting Injection (RLAI)
- **DRUG:** Risperidone Long-Acting Injection (RLAI)

## Key facts

- **NCT ID:** NCT00378092
- **Lead sponsor:** Janssen Cilag N.V./S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378092, "A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00378092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*